I0097
IHC-HER-2/neu
Test Details: Immunohistochemical testing helps to identify specific antigens (proteins) within tissue sections utilizing an antigen-specific antibody. The overexpression of HER-2 is noted mainly in breast and gastric adenocarcinomas, in addition to a subset of other carcinoma types such as ovarian carcinoma, non-small cell carcinoma of the lung, salivary gland carcinoma, and urinary bladder transitional cell carcinoma. Over-expression of HER2/neu is associated with poor prognosis of breast, ovarian, bladder, pancreatic, stomach, and oesophageal malignancies. It is a predictive marker for a positive response to a monoclonal antibody, trastuzumab, targeted against the HER2/neu receptor.
![](assets/img/diagnleftimg.png)
Category
Advanced Routine Diagnostics
Pre-test Information
Demographic data, site of the specimen, clinical details & relevant investigations including radiology are mandatory.
Report Delivery
4 days after releasing H&E report
Gender
Female
Organ
Multi-Organ
IHC-HER-2/neu
1570
Most Searched Diagnostic Tests